Research
From fundamental insights on information and biological order to pioneering epigenetic platforms — our research architecture is built for depth, coherence, and long-term impact.
Foundational Research
Scientific progress does not emerge from isolated discoveries, but from coherent frameworks that allow complexity to be understood, modeled, and translated into action.
At the origin of REGENEVIA lies a long-standing program of fundamental research on information, order, and biological organization. This research explored how complex systems — from physical structures to living cells — maintain stability, identity, and function over time, and how these properties degrade with entropy and aging.
This central insight — that biological aging reflects an erosion of informational order rather than simple mechanical wear — became the conceptual foundation for all subsequent research at Regenevia.
Core Research Areas
Epigenetic Modulation
Controlled partial cellular reprogramming strategies that reset epigenetic age markers without erasing cellular identity, enabling targeted rejuvenation of specific tissues and organs.
Information Theory in Biology
Application of information-theoretic frameworks to understand how biological systems encode, maintain, and lose regulatory coherence over time — bridging physics and biology.
Systems Biology
Multi-omics integration and computational modeling to map the complex interplay between epigenetic layers, gene expression networks, and cellular function across the lifespan.
Translational Platforms
Development of proprietary research platforms designed from inception for industrial collaboration, clinical translation, and scalable application in regenerative medicine.
Intellectual Property Portfolio
Innovation at Regenevia is deliberately structured. From early-stage concepts to advanced research platforms, intellectual property considerations are integrated into every phase of development. Our portfolio includes 5 USPTO patents covering:
Autologous 3D Micro-Tissue Generation
An innovative system for generating personalized autologous serums using advanced 3D micro-tissue technology for regenerative medicine applications.
System of Aging Reversal
A comprehensive system for reversing biological aging through controlled epigenetic reprogramming — a multi-phase protocol combining cellular rejuvenation and systemic optimization.
Personalized Autologous Serum
Method for producing personalized serums derived from patient’s own epithelial cells stimulated with a patented molecular cocktail containing EGF, VEGF, TGF-β, IGF-1, GDF-11, TIMP-2.
Biologically Active Fillers
Advanced method for producing biologically active autologous fillers yielding rich extracellular matrix containing collagen types I and III, elastin, and hyaluronic acid.
Genesis7 Systemic Serum
Groundbreaking method for preparing a systemic autologous bioactive serum for deep systemic rejuvenation, administered via intravenous infusion with DNA methylation monitoring.
Advanced Research Platform: E.S.D.C.
Epigenetic Scanner for Diagnosis and Command
The E.S.D.C. represents the next frontier in regenerative medicine: a conceptual platform that integrates multi-omic epigenetic mapping, an epigenetic command module for delivering safe and reversible molecular instructions, a selective elimination module for pathological tissues, and a pro-regenerative microenvironment system.
Central to the platform is the composite index ψ-One, designed to quantify the “epigenetic order” of tissues and to steer therapeutic decisions through real-time feedback. The goal is to enable in-situ regeneration while reducing reliance on transplantation and large-scale cell infusions.
This work is documented in a USPTO provisional patent application (2025) and an accompanying preprint publication.
USPTO Patent Application · Open Access Preprint
Explore Further
Our research is documented through peer-reviewed publications, patent filings, and scientific communications.
REGENEVIA BIO
Epigenetic Science & Cellular Reprogramming Research
Privacy Policy · Terms of Use · Disclaimer | Cookie Policy
© 2025 Regenevia Bio. All rights reserved. Part of the Linchi Group.